非诺贝特咀嚼片治疗高脂血症的疗效观察

Efficacy of fenofibrate chewable tablets in the treatment of hyperlipidemia

目的观察非诺贝特咀嚼片治疗高脂血症的有效性和安全性。方法在北京五所医院选择血浆甘油三酯水平≥2．26mmol／L的患者100例，按随机号分为咀嚼片组和胶囊组2组，分别给予非诺贝特咀嚼片及非诺贝特胶囊200mg／d，共治疗8周。治疗前后测定血脂及安全参数并进行分析，记录药物不良反应情况。结果与治疗前比，治疗8周后2组患者的甘油三酯水平均有显著的下降，高密度脂蛋白胆固醇水平明显升高。咀嚼片组与胶囊组降低甘油三酯及升高高密度脂蛋白胆固醇效果相似，差异无统计学意义（分别为44．88％与45．11％及16．51％与13．35％，P〉0．05），2组总体疗效接近（84．1％与86．7％，P〉0．05）。结论非诺贝特咀嚼片降低甘油三酯及升高高密度脂蛋白胆固醇效果理想，安全性较好。

Objective To evaluate the efficacy and safety of fenofibrate chewable tablets for hyperlipidemic. Methods One hundred patients with serum tfiglyceride equal to or above 2.26 mmol/L were included. Patients were randomized to fenofibrate chewable tablets （200 mg once a day）group and fenofibrate capsules（200 mg once a day） group for 8 weeks. Results At 8 weeks, administration of two dosage forms of fenofibrate all reduced serum triglycerides （P 〈 0.01 ） and evoked a significant increase in serum high-density lipeprotein （HDL） cholesterol levels （ P 〈 0.01 ）. Median decrease of serum triglycerides was 44.88 % and 45.11% in fenofibrate chewable tablets group and fenofibrate capsules group respectively. Mean increase of serum HDL-C holesterol in both groups was 16.51% and 13.35%, respectively. Curative effect of the hyperlipidemia in the fenofibrate chewable tablets group was 84.1% and 86.7% in fenofibrate capsules group. Conclusion Fenofibrate chewable tablets with 200 mg/day showes significant lipid-modifying properties. Efficacy of fenofibrate chewable tablets for treatment of hyperlipidemia has the same effect as fenofibrate capsules.